Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04797260




Registration number
NCT04797260
Ethics application status
Date submitted
11/03/2021
Date registered
15/03/2021
Date last updated
18/04/2024

Titles & IDs
Public title
Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID
Scientific title
Phase I/II Clinical Trial of Autologous Hematopoietic Stem Cell Gene Therapy in RAG1-Deficient Severe Combined Immunodeficiency
Secondary ID [1] 0 0
L20.067
Universal Trial Number (UTN)
Trial acronym
RAG1-SCID
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Severe Combined Immunodeficiency Due to RAG1 Deficiency 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Gene therapy

Experimental: Gene therapy - In this arm, 10 patients will be included for gene therarpy


Treatment: Other: Gene therapy
Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Feasibility of successful generation of RAG1 LV CD34+ cells
Timepoint [1] 0 0
2 years
Primary outcome [2] 0 0
Safety of RAG1 lentiviral gene therapy
Timepoint [2] 0 0
2 years
Secondary outcome [1] 0 0
T cell reconstitution
Timepoint [1] 0 0
1 year
Secondary outcome [2] 0 0
Thymic function
Timepoint [2] 0 0
1 year
Secondary outcome [3] 0 0
T and B cell receptor repertoire
Timepoint [3] 0 0
1 year
Secondary outcome [4] 0 0
Immunoglobulin dependence
Timepoint [4] 0 0
2 years
Secondary outcome [5] 0 0
Persistence of gene marking
Timepoint [5] 0 0
1 year
Secondary outcome [6] 0 0
Occurrence of Infections
Timepoint [6] 0 0
2 years
Secondary outcome [7] 0 0
Failure to thrive
Timepoint [7] 0 0
2 years
Secondary outcome [8] 0 0
Quality of life
Timepoint [8] 0 0
2 years

Eligibility
Key inclusion criteria
1. RAG1-deficient SCID as confirmed by genetic analysis
2. Peripheral blood T cells < 300/µL and/or naïve T cells < 1/µL
3. Age < 2 years
4. Age at least 8 weeks by the time of busulfan and fludarabine administration
5. Lack of an available HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ) allele-matched (un)related donor)
6. Signed informed consent (parental or guardian)
7. Able to return to the study centre for follow-up (per protocol) during the 2-year study and the 15-year long-term off study review
Minimum age
8 Weeks
Maximum age
24 Months
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Availability of an HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ) allele-matched (un)related donor)
2. RAG1 deficiency with peripheral blood T cells > 300/µL and/or naïve T cells > 1/µL
3. Omenn syndrome
4. Previous allogeneic HSCT
5. Significant organ dysfunction/co-morbidity (including but not limited to the ones listed below):

1. Mechanical ventilation
2. Shortening fraction on echocardiogram <25%
3. Renal failure defined as dialysis dependence
4. Uncontrolled seizure disorder
6. Any other condition that the investigator considers is a contraindication to collection and/or infusion of trans-duced cells for that individual or indicate patient's inability to follow the protocol, for example contraindication f to busulfan, major congenital abnormalities, ineligible to receive anaesthesia, or documented refusal or inability of the family to return for scheduled visits.
7. Human immunodeficiency virus (HIV) infection or Human T-cell Leukemia Virus (HTLV) infection

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/07/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2029
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Royal Childrens Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3052 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Italy
State/province [1] 0 0
Roma
Country [2] 0 0
Netherlands
State/province [2] 0 0
Leiden
Country [3] 0 0
Poland
State/province [3] 0 0
Wroclaw
Country [4] 0 0
Spain
State/province [4] 0 0
Barcelona
Country [5] 0 0
Turkey
State/province [5] 0 0
Kayseri
Country [6] 0 0
United Kingdom
State/province [6] 0 0
London

Funding & Sponsors
Primary sponsor type
Other
Name
Leiden University Medical Center
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
ZonMw: The Netherlands Organisation for Health Research and Development
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Horizon 2020 - European Commission
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is a prospective, non-randomized, open-label, two-centre phase I/II intervention study designed to treat children up to 24 months of age with RAG1-deficient SCID with an indication for allogeneic hematopoietic stem cell transplantation but lacking an HLA-matched donor. The study involves infusion of autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (hereafter called RAG1 LV CD34+ cells) in five patients with RAG1-deficient SCID.
Trial website
https://clinicaltrials.gov/study/NCT04797260
Trial related presentations / publications
Garcia-Perez L, van Eggermond M, van Roon L, Vloemans SA, Cordes M, Schambach A, Rothe M, Berghuis D, Lagresle-Peyrou C, Cavazzana M, Zhang F, Thrasher AJ, Salvatori D, Meij P, Villa A, Van Dongen JJM, Zwaginga JJ, van der Burg M, Gaspar HB, Lankester A, Staal FJT, Pike-Overzet K. Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID. Mol Ther Methods Clin Dev. 2020 Mar 31;17:666-682. doi: 10.1016/j.omtm.2020.03.016. eCollection 2020 Jun 12.
Public notes

Contacts
Principal investigator
Name 0 0
Arjan C Lankester, Prof.dr.
Address 0 0
Leiden University Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Arjan C Lankester, Prof. Dr.
Address 0 0
Country 0 0
Phone 0 0
0031715264871
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04797260